$MAZE insider trading
Over the last 12 months, Maze Therapeutics insiders reported no purchases and 40 sales totaling $21.1M across SEC Form 4 filings. 85% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $21.1M 40 events
- Events · 12m
- 40 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 85% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Courtney PhillipsGC and Corp. Secretary · O | ▼ Sale | 3,993 | $26.24 | $105K | -36.3% | 4 tranches |
| Sep 3, 2026 | Dandekar AtulCSBO · O | ▼ Sale | 6,434 | $26.24 | $169K | -16.6% | 4 tranches |
| Sep 3, 2026 | Coloma Jason VChief Executive Officer · O·D | ▼ Sale | 22,638 | $26.24 | $594K | -45.3% | 4 tranches |
| Sep 3, 2026 | Bernstein HaroldPresident, R&D & CMO · O | ▼ Sale | 10,295 | $26.24 | $270K | -51.5% | 4 tranches |
| Sep 1, 2026 | Coloma Jason VChief Executive Officer · O·D | ▼ Sale | 34,501 | $26.29 | $907K | -13.4% | plan · 2 tranches · indirect |
| Sep 1, 2026 | Bernstein HaroldPresident, R&D & CMO · O | ▼ Sale | 16,141 | $26.36 | $426K | -100% | plan |
| Aug 28, 2026 | Dandekar AtulCSBO · O | ▼ Sale | 7,500 | $27.58 | $207K | -22.2% | plan |
| Aug 13, 2026 | Bernstein HaroldPresident, R&D & CMO · O | ▼ Sale | 16,142 | $27.61 | $446K | -100% | plan |
| Aug 3, 2026 | Coloma Jason VChief Executive Officer · O·D | ▼ Sale | 34,501 | $26.73 | $922K | -11.9% | plan · 4 tranches · indirect |
| Jul 29, 2026 | Dandekar AtulCSBO · O | ▼ Sale | 7,500 | $27.34 | $205K | -22.2% | plan · 2 tranches |
| Jul 1, 2026 | Bernstein HaroldPresident, R&D & CMO · O | ▼ Sale | 14,609 | $29.9 | $437K | -100% | plan · 2 tranches |
| Jul 1, 2026 | Coloma Jason VChief Executive Officer · O·D | ▼ Sale | 34,501 | $29.98 | $1.0M | -10.7% | plan · 3 tranches · indirect |
| Jun 29, 2026 | Dandekar AtulCSBO · O | ▼ Sale | 7,500 | $28.02 | $210K | -22.2% | plan |
| Jun 23, 2026 | Coloma Jason VChief Executive Officer · O·D | ▼ Sale | 27,858 | $26.04 | $725K | -8% | plan · 3 tranches · indirect |
| Jun 1, 2026 | Coloma Jason VChief Executive Officer · O·D | ▼ Sale | 553 | $26.24 | $15K | -1.9% | plan · indirect |
| Jun 1, 2026 | Coloma Jason VChief Executive Officer · O·D | ▼ Sale | 6,090 | $26.2 | $160K | -1.7% | plan · indirect |
| Jun 1, 2026 | Bernstein HaroldPresident, R&D & CMO · O | ▼ Sale | 1,600 | $26.36 | $42K | -100% | plan |
| Jun 1, 2026 | Bernstein HaroldPresident, R&D & CMO · O | ▼ Sale | 13,253 | $25.57 | $339K | -89.2% | plan |
| May 29, 2026 | Dandekar AtulCSBO · O | ▼ Sale | 7,500 | $26.34 | $198K | -23.2% | plan |
| May 22, 2026 | Coloma Jason VChief Executive Officer · O·D | ▼ Sale | 4,504 | $26 | $117K | -1.2% | plan · indirect |
| Apr 29, 2026 | Dandekar AtulCSBO · O | ▼ Sale | 7,500 | $25.37 | $190K | -41.7% | plan |
| Apr 1, 2026 | Bachrodt AmySVP, Finance · O | ▼ Sale | 2,500 | $29.44 | $74K | -16.2% | plan · 2 tranches |
| Apr 1, 2026 | Bernstein HaroldPresident, R&D & CMO · O | ▼ Sale | 15,000 | $29.46 | $442K | -100% | plan · 3 tranches |
| Mar 30, 2026 | Dandekar AtulCSBO · O | ▼ Sale | 7,500 | $29.34 | $220K | -41.7% | plan · 2 tranches |
| Mar 20, 2026 | Bernstein HaroldPresident, R&D & CMO · O | ▼ Sale | 15,000 | $49.1 | $736K | -100% | plan · 3 tranches |
| Mar 10, 2026 | Bernstein HaroldPresident, R&D & CMO · O | ▼ Sale | 30,000 | $50.45 | $1.5M | -100% | plan · 2 tranches |
| Mar 2, 2026 | Bachrodt AmySVP, Finance · O | ▼ Sale | 5,000 | $45.2 | $226K | -27.8% | plan · 2 tranches |
| Feb 27, 2026 | Dandekar AtulCSBO · O | ▼ Sale | 7,500 | $45.43 | $341K | -41.7% | plan · 2 tranches |
| Feb 2, 2026 | Bachrodt AmySVP, Finance · O | ▼ Sale | 5,000 | $46.04 | $230K | -27.8% | plan · 3 tranches |
| Feb 2, 2026 | Bernstein HaroldPresident, R&D & CMO · O | ▼ Sale | 15,000 | $46.02 | $690K | -100% | plan · 4 tranches |
| Jan 29, 2026 | Dandekar AtulCSBO · O | ▼ Sale | 7,500 | $44.27 | $332K | -41.7% | plan · 3 tranches |
| Jan 22, 2026 | Bachrodt AmySVP, Finance · O | ▼ Sale | 5,000 | $45.52 | $228K | -27.8% | plan |
| Jan 7, 2026 | Bernstein HaroldPresident, R&D & CMO · O | ▼ Sale | 25,156 | $40.2 | $1.0M | -100% | plan |
| Jan 7, 2026 | Sohn Catherine A.D | ▼ Sale | 29,413 | $39.07 | $1.1M | -100% | 2 tranches |
| Jan 5, 2026 | Bernstein HaroldPresident, R&D & CMO · O | ▼ Sale | 4,844 | $40.39 | $196K | -100% | plan · 2 tranches |
| Jan 2, 2026 | Bachrodt AmySVP, Finance · O | ▼ Sale | 5,000 | $39.15 | $196K | -27.8% | plan · 2 tranches |
| Dec 30, 2025 | Bachrodt AmySVP, Finance · O | ▼ Sale | 15,000 | $40.41 | $606K | -53.6% | plan · 3 tranches |
| Dec 30, 2025 | Dandekar AtulCSBO · O | ▼ Sale | 72,500 | $40.56 | $2.9M | -87.3% | plan · 3 tranches |
| Dec 29, 2025 | Bernstein HaroldPresident, R&D & CMO · O | ▼ Sale | 45,000 | $40.56 | $1.8M | -100% | plan · 2 tranches |
| Sep 15, 2025 | SCHELLER RICHARD HD | ▼ Sale | 20,744 | $22.37 | $464K | -100% | — |
Every $MAZE filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Maze Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MAZE feed.